在着床时单次给予促性腺激素释放激素（GnRH）激动剂可增强胚胎发育潜能。
Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation.
作者信息
Tesarik Jan, Hazout André, Mendoza Carmen
机构信息
MAR&Gen, Molecular Assisted Reproduction & Genetics, Gracia 36, 18002 Granada, Spain.
出版信息
Hum Reprod. 2004 May;19(5):1176-80. doi: 10.1093/humrep/deh235. Epub 2004 Apr 7.
BACKGROUND
Several reports have shown that inadvertent administration of a GnRH agonist in the luteal phase does not compromise pregnancy. Moreover, some studies suggested that, unexpectedly, the embryo developmental potential is improved in these conditions. This prospective controlled study was designed to test this hypothesis.
METHODS
In an oocyte donation programme, oocytes from each donor (n = 138) were shared by two recipients, one of whom was given a single dose of a GnRH agonist (0.1 mg triptorelin) 6 days after ICSI, and the other received placebo at the same time.
RESULTS
Oocyte recipients treated with GnRH agonist 6 days after ICSI had higher implantation (36.9 versus 25.1%), twin pregnancy (16.7 versus 3.6%), twin delivery (13.8 versus 2.2%) and birth (31.1 versus 21.5%) rates and similar miscarriage and abortion rates as compared with the placebo group.
CONCLUSIONS
GnRH agonist administration at the time of implantation enhances embryo developmental potential, probably by a direct effect on the embryo.
背景
多项报告显示，在黄体期意外使用促性腺激素释放激素（GnRH）激动剂不会影响妊娠。此外，一些研究表明，在这些情况下，胚胎发育潜能意外得到改善。本前瞻性对照研究旨在验证这一假设。
方法
在一项卵母细胞捐赠计划中，每位供体（n = 138）的卵母细胞由两名受者共享，其中一名受者在卵胞浆内单精子注射（ICSI）后6天给予一剂GnRH激动剂（0.1 mg曲普瑞林），另一名受者同时接受安慰剂。
结果
与安慰剂组相比，ICSI后6天接受GnRH激动剂治疗的卵母细胞受者着床率（36.9%对25.1%）、双胎妊娠率（16.7%对3.6%）、双胎分娩率（13.8%对2.2%）和出生率（31.1%对21.5%）更高，流产和堕胎率相似。
结论
着床时给予GnRH激动剂可提高胚胎发育潜能，可能是通过对胚胎的直接作用实现的。
Zotero 插件